Abstract: A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 ?M or urine with a normal biologic range of between about 0-1000 ?M.
Type:
Application
Filed:
May 16, 2013
Publication date:
May 28, 2015
Applicant:
LipoScience, Inc.
Inventors:
James D. Otvos, Elias J. Jeyarajah, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Dennis W. Bennett, Steven P. Matyus
Abstract: The clinical analyzers automatically electronically monitor selected parameters and automatically electronically adjust parameters to maintain the analyzer within desired operational ranges. The clinical NMR analyzers can be configured as a networked system with a plurality of clinical NMR analyzers located at different use sites.
Type:
Application
Filed:
March 6, 2014
Publication date:
July 3, 2014
Applicant:
LipoScience, Inc.
Inventors:
James D. Otvos, Elias J. Jeyarajah, Stephen Markham, Steven P. Matyus, David R. Morgan, Bruce D. Silberman, Donald R. Deuel
Abstract: The clinical analyzers automatically electronically monitor selected parameters and automatically electronically adjust parameters to maintain the analyzer within desired operational ranges. The clinical NMR analyzers can be configured as a networked system with a plurality of clinical NMR analyzers located at different use sites.
Type:
Grant
Filed:
August 11, 2011
Date of Patent:
April 22, 2014
Assignee:
LipoScience, Inc.
Inventors:
James D. Otvos, Elias J. Jeyarajah, Stephen Markham, Steven P. Matyus, David R. Morgan, Bruce D. Silberman, Donald R. Deuel
Abstract: Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of “GlycA” in arbitrary units or in defined units (e.g., ?mol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.
Type:
Application
Filed:
March 14, 2013
Publication date:
December 12, 2013
Applicant:
LipoScience, Inc.
Inventors:
James D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore
Abstract: Methods, reports and systems for generating insulin resistance indexes for assessing decreased insulin sensitivity and/or levels of insulin resistance using a plurality of different measured lipoprotein particle parameters.
Abstract: Methods, computer program products and apparatus automate clinical NMR in vitro diagnostic analyzers. The clinical analyzer can automatically electronically monitor selected parameters and automatically electronically adjust parameters to maintain the analyzer within desired operational ranges. The clinical NMR analyzers can be configured as a networked system with a plurality of clinical NMR analyzers located at different use sites; and at least one remote control system in communication with one or a plurality of clinical NMR analyzers, the at least one remote system configured to monitor selected local operating parameters associated with a respective clinical NMR analyzer.
Type:
Grant
Filed:
March 30, 2005
Date of Patent:
September 6, 2011
Assignee:
LipoScience, Inc.
Inventors:
James D. Otvos, Elias J. Jeyarajah, Stephen Markham, Steven P. Matyus, David R. Morgan, Bruce D. Silberman, Donald R. Deuel
Abstract: Methods, computer program products and apparatus determine a subject's risk of having or developing CHD using a calculated LDL particle risk number and/or a mathematical model of risk associated with LDL particles that adjusts concentrations of at least one of small and large LDL particle measurements to reflect predicted CHD risk.
Abstract: Methods, systems and computer programs are configured to determine the presence of and/or a measurement for a plurality of constituents in a composite signal with closely correlated chemical constituents having overlapping signal lineshapes extending about a spectrum of interest obtained from a target sample undergoing analysis.
Type:
Grant
Filed:
October 22, 2003
Date of Patent:
July 10, 2007
Assignee:
LipoScience, Inc.
Inventors:
Russell Reeve, Elias Jeyarajah, Dennis Bennett
Abstract: Methods for assessing a patient's risk of having or developing coronary heart disease based on lipoprotein measurements measure and identify values for lipoprotein subclass constituents and analyze according to predetermined test criteria to identify when there is an increased and/or decreased risk of having and/or developing coronary heart disease associated wit the measured lipoprotein subclass constituent values.
Abstract: A method of screening a subject for the presence of lipoprotein X includes the steps of: producing a measured lipid signal lineshape of an NMR spectrum of a blood plasma or serum sample obtained from a subject; generating a calculated lineshape for the sample, the calculated lineshape being based on derived concentrations of lipoprotein components potentially present in the sample, the derived concentration of each of the lipoprotein components being the function of a reference spectrum for that component and a calculated reference coefficient, wherein one of the lipoprotein components for which a concentration is calculated is lipoprotein X; and determining the degree of correlation between the calculated lineshape of the sample and the measured lineshape spectrum of the sample.
Type:
Grant
Filed:
July 30, 2002
Date of Patent:
September 9, 2003
Assignee:
LipoScience, Inc.
Inventors:
James D. Otvos, Elias J. Jeyarajah, Irina Y. Shalaurova
Abstract: A method for analyzing a patient's risk of coronary heart disease by determining the presence of NMR-derived or based lipoprotein constituent value abnormalities includes determining the presence of atherogenic dyslipidemia based on the existence of a clustering of lipoprotein constituent abnormalities as defined by predetermined test criteria. Computer program products and automatically produced reports for presenting NMR-derived lipoprotein risk assessment based on patient-specific lipoprotein subclass results present the measurement results adjacent to a segmented reference risk analysis portion. The actual measured results are visually aligned and enhanced within the risk analysis portion to provide easy reference and understanding of the results relative to a risk of developing coronary heart disease.
Abstract: Methods for assessing the risk of developing Type 2 diabetes and other related disorders include obtaining an NMR derived reference spectrum for a known glucose concentration sample and storing this information as a reference standard. A patient blood sample is collected and NMR derived patient spectrums for the blood sample are obtained. The two NMR data sets (the reference and the patient) are compared and a glucose concentration is determined for the patient sample. The glucose concentration can be evaluated with a blood sample undergoing lipoprotein cholesterol evaluation. The NMR based test can be used to concurrently provide a glucose concentration and lipoprotein constituent values based on a single testing event. The disclosure also includes a multi-purpose test, i.e., a test which concurrently provides lipoprotein screening and coronary heart disease risk evaluation along with a diabetes screening and risk assessment for developing Type 2 diabetes.
Type:
Grant
Filed:
April 19, 2000
Date of Patent:
February 11, 2003
Assignees:
LipoScience, Inc., North Carolina State University